![Kathryn Gallaway, MD (@ke_gallaway) 's Twitter Profile](https://pbs.twimg.com/profile_images/1691639298133770241/XaTouUs5_200x200.jpg)
Kathryn Gallaway, MD
@ke_gallaway
34 y/o G2P2 presents w/ insatiable thirst for knowledge of unknown etiology | Philosophy @RiceUniversity | MD @UTSWNews | Associate Medical Director @DAVAOnc
ID: 1558842292605259777
https://www.linkedin.com/in/kathryn-gallaway-845136236/ 14-08-2022 15:46:19
958 Tweet
383 Followers
917 Following
![Kathryn Gallaway, MD (@ke_gallaway) 's Twitter Profile Photo Kathryn Gallaway, MD (@ke_gallaway) 's Twitter Profile Photo](https://pbs.twimg.com/profile_images/1691639298133770241/XaTouUs5_200x200.jpg)
Phenomenal work from Mark Roschewski diving into the biology and treatment strategies of immune privileged LBCL ashpublications.org/blood/article-… Looking forward to updated data from trials considering response adapted chemo after ibrutinib a window study for acalabrutinib
![Kathryn Gallaway, MD (@ke_gallaway) on Twitter photo Phenomenal work from <a href="/RoschewskiMD/">Mark Roschewski</a> diving into the biology and treatment strategies of immune privileged LBCL
ashpublications.org/blood/article-…
Looking forward to updated data from trials considering response adapted chemo after ibrutinib a window study for acalabrutinib Phenomenal work from <a href="/RoschewskiMD/">Mark Roschewski</a> diving into the biology and treatment strategies of immune privileged LBCL
ashpublications.org/blood/article-…
Looking forward to updated data from trials considering response adapted chemo after ibrutinib a window study for acalabrutinib](https://pbs.twimg.com/media/GUiyEZpXwAAxSj9.jpg)